CLOs on the Move

Tia

www.asktia.com

 
Founded in 2017 by Carolyn Witte and Felicity Yost, Tia is bringing the new standard of care for women for women in NY, LA, SF and PHX. Blending in-person and virtual care services, Tia`s “Whole Woman, Whole Life” care model fuses gynecology, primary care, mental health and evidence-based wellness services to treat women comprehensively. By bringing collaborative, comprehensive, and compassionate care, Tia is raising the bar for women and empowering them to achieve optimal health, on their terms.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.asktia.com
  • 548 Market Street Suite 45295
    San Francisco, CA USA 94104
  • Phone: 855.586.1306

Executives

Name Title Contact Details
Jessica Tomlinson
 General Counsel Profile

Similar Companies

Blue Cross and Blue Shield of Mississippi (BCBSMS)

Blue Cross & Blue Shield of Mississippi (BCBSMS) is a Jackson, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advocare Group

Advocare Group is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

mTuitive

mTuitive is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Centerville, MA. To find more information about mTuitive, please visit www.mtuitive.com

Health Information Technology Care

Health Information Technology Care is a Petaluma, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Telesta Therapeutics

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.